Dong Sifan, Gao Yunlong, Wang Zhe, Liang Jinqiang, Jiang An
Xi'an Jiaotong University, Xi'an, China.
Hepatobiliary, Pancreatic and Liver Transplantation surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
J Cancer Res Clin Oncol. 2025 Jul 3;151(7):200. doi: 10.1007/s00432-025-06180-3.
Pancreatic cancer has a high degree of malignancy, poor prognosis, and short survival time. Surgical resection is the main treatment for pancreatic cancer, but the resection rate is only 20%. Liver metastases are the main reason of unresectable. The conversion therapy for pancreatic cancer with liver metastases is rare and less reported.
A 52-year-old male patient with pancreatic cancer and multiple liver metastases was reported. Imaging examination showed multiple low-density shadows in the liver. Laboratory tests showed elevated levels of pro-gastrin-releasing peptide and CEA. After gemcitabine combined with albumin-bound paclitaxel chemotherapy, the liver metastases disappeared and the primary pancreatic head tumor was significantly reduced. Pancreaticoduodenectomy was performed, and the patient recovered well without any other adjuvant therapy. The patient has been alive for 36 months without tumor recurrence.
The efficacy of Gemcitabine combined with Albumin-bound paclitaxel in conversion therapy for pancreatic cancer patients with multiple liver metastases may be related to the size and duration of metastases, which needs to be further studied.
胰腺癌具有高度恶性、预后差和生存时间短的特点。手术切除是胰腺癌的主要治疗方法，但切除率仅为20%。肝转移是无法切除的主要原因。胰腺癌伴肝转移的转化治疗罕见且报道较少。
报告了一名52岁男性胰腺癌伴多发肝转移患者。影像学检查显示肝脏有多个低密度阴影。实验室检查显示胃泌素释放肽前体和癌胚抗原水平升高。吉西他滨联合白蛋白结合型紫杉醇化疗后，肝转移灶消失，胰腺头部原发肿瘤明显缩小。行胰十二指肠切除术，患者恢复良好，未进行任何其他辅助治疗。患者已存活36个月，无肿瘤复发。
吉西他滨联合白蛋白结合型紫杉醇在胰腺癌伴多发肝转移患者转化治疗中的疗效可能与转移灶的大小和持续时间有关，有待进一步研究。
